A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

bNational Institute of Health and Care Research (NIHR) Blood and Transplant Research Unit (BTRU) in Precision Cellular Therapeutics, University of Birmingham, Birmingham, UK cNIHR Biomedical Research ...

Cytotoxicity assays using anti-PNE CAR-T cells and different concentrations of PNE-tagged HER2 Fab switches were performed using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) based on ...

CAR T-cell therapies offer high response rates but face logistical challenges, including lengthy "brain-to-vein" times and high costs, limiting their accessibility. Bispecific therapies are more ...

The off-the-shelf CAR-T cell therapy specialist disclosed the changes alongside delays to two milestones. California-based Allogene has three clinical programs. Tuesday, the company disclosed ...

Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in a phase 1/2 study. Patients received their CAR-T within 8 to 12 days of lymphodepletion.